Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency.

steroid therapy
soft tissue lesion
bone metastases
prednisone
solid tumour
  • 0 views
  • 19 Feb, 2024
EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer

This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects.

digital rectal exam
prostate adenocarcinoma
androgens
pelvic mri
adenocarcinoma of prostate
  • 0 views
  • 19 Feb, 2024
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

ct scan
prostate cancer
adenocarcinoma
hormone therapy
tumor progression
  • 0 views
  • 19 Feb, 2024
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the …

gonadotropin
eligard
bone metastases
ct scan
adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Lutetium-177-PSMA-I&T in Oligo-metastatic Hormone Sensitive Prostate Cancer

  Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. In the last few years, several lutetium-177 (177Lu, emitter) labeled PSMA ligands have been …

androgens
docetaxel
dutasteride
abiraterone
enzalutamide
  • 4 views
  • 19 Feb, 2024
Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer

Studies have suggested that simultanously treatment with androgen deprivation therapy during radiation therapy may be able to proctect stemcells in the bladder, thus improving tissue recovering post-radiation, which would result in improved bladder compliance following the treatment and ultimately result in fewer side effects and overall improved patient quality of …

cancer radiation therapy
androgen
bladder cancer
cancer
endocrine therapy
  • 0 views
  • 19 Feb, 2024